Table 1. Patients’ characteristics.
| Characteristics | FOLFIRI+B*12 (N=101) | FOLFIRI+B*6 (N=97) | P value$ |
|---|---|---|---|
| Sex, female:male | 34%:66% | 42%:58% | 0.2133 |
| Age, median (range) | 65years (34-81) | 66years (26-80) | 0.1531 |
| Primary, right vs left colon | 22% vs 78% | 30% vs 70% | 0.2163 |
| Months since diagnosis, median(range) | 2 (1-93) | 2 (1-76) | 0.4896 |
| Grading, % of grade 1-2 vs grade 3 | 63% v 37% | 74% v 26% | 0.1848 |
| Resection of the primary | 77% | 72% | 0.4136 |
| ECOG PS, 0:1 | 81%:19% | 80%:20% | 0.8901 |
| Alkaline Phosphatase , % > ULN | 9% | 4% | 0.1755 |
| LDH, % > ULN | 18% | 12% | 0.4545 |
| WBC, median (range) | 7 #/mm3(2.6-16.8) | 6.6 #/mm3 (3.2-17.2) | 0.1558 |
| Neutrophils, median (range) | 4.3 #/mm3 (1.7-16.7) | 4.0 #/mm3 (1.4-13.5) | 0.1098 |
| Hemoglobin, median (range) | 12.3 g/dL (8-16) | 12.1 g/dL (8.8-16.1) | 0.5318 |
| Platelets, median (range) | 254 #/mm3 (112-595) | 260 #/mm3 (105-552) | 0.9203 |
| CEA, median (range) | 24.4 mcg/mL (0.2-5518) | 16.6 mcg/mL (0.1-5501) | 0.6684 |
| CA19.9, median (range) | 35.7 UI/mL (0.1-44587) | 31.9 UI/mL (0.6-203600) | 0.7753 |
| # of metastatic sites, % 1 vs ≥2 | 36% v 64% | 40% v 60% | 0.3131 |
Values refer to percentage of patients, unless otherwise specified. B: bevacizumab; ECOG PS: Eastern Cooperative Oncology Group Performance Status; ULN: upper limit of normal; LDH: lactate dehydrogenase; WBC: white blood cells.
$P values are calculated using chi-square test for categorical variables and t-test for continuous variables.